Skip to main content

Advertisement

Table 2 Summary of patient characteristics

From: Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

Characteristics Responders (n = 12) Non-responders (n = 12) P value
Age – no. (%)
  > 65 6 (50%) 2 (17%) 0.083
  ≤ 65 6 (50%) 10 (83%)  
Sex – no. (%)
 Male 9 (75%) 9 (75%) >0.999
 Female 3 (25%) 3 (25%)  
LDH – no. (%)
  > 1× ULN 1 (8%) 8 (67%) 0.0032
  ≤ 1× ULN 11 (92%) 4 (33%)  
Disease volume – no. (%)
 SPOD > 1000 mm2 7 (58%) 10 (83%) 0.178
 SPOD ≤ 1000 mm2 5 (42%) 2 (17%)  
AJCC tumor stage – no. (%)
 M1a or M1b 6 (50%) 1 (8%) 0.025
 M1c 6 (50%) 11 (92%)  
Mutation – no. (%)
 BRAFV600E/K 3 (25%) 5 (42%) 0.3865
 Non-BRAFV600E/K 9 (75%) 7 (58%)  
  1. Abbreviations: LDH lactate dehydrogenase, SPOD sum of product of diameters, AJCC American Joint Committee on Cancer, ULN upper limit of normal. The p value was calculated using the Chi square test for a two by two contingency table